Treatment of Gliomas with Anti-B7H3 CAR-T Cells

Stanford researchers have developed a strategy for using anti-B7H3 CAR-T cells in a more effective manner for the treatment of glioma.

High grade gliomas are the leading cause of brain tumor death in adults. However, available treatments often have limited efficacy and are associated with severe side effects. Stanford researchers therefore developed a specific protocol for treating glioma using CAR-T cells engineered to target B7H3, an antigen that is highly expressed only on cancer cells. The clinical protocol is for patients who have had surgical resection of brain tumor cells and identifies the optimal dose and timing of administration of CAR-T cells based on patient's inflammatory response. In an ongoing phase I clinical trial, this regimen results in decreased tumor volume and may provide benefit for overall survival of an individual being treated.

Stage of Development
In phase I clinical trial for recurrent glioblastoma multiforme (GBM)